Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, has provided an update on its pending acquisition by Cycle Group Holdings Limited, a UK-based company specializing in rare genetic conditions. The company confirmed that the offer period for Cycle's subsidiary, AT2B, Inc., to purchase Applied Therapeutics shares has been extended. Applied Therapeutics reiterated that, after considering alternative strategic options and not receiving any competing proposals since the agreement was signed on December 11, 2025, the transaction with Cycle remains the best available option for maximizing stockholder value. The company also noted that if the transaction is not completed, the share price could decline, especially if current trading levels reflect expectations that the deal will close. This update was disclosed in a letter to stockholders from Applied Therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Applied Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9645308-en) on January 29, 2026, and is solely responsible for the information contained therein.